Elizabeth Sarmiento

Elizabeth Sarmiento

Auto-generated profile, based on publicly available information

Elizabeth Sarmiento

Clinical Immunology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2007 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
PMPatricia Munoz
Patricia Munoz
Maddalena GiannellaMaddalena Giannella
Maddalena Giannella
LALuís Alcalá
Luís Alcalá
ESElisabeth Sarmiento
Elisabeth Sarmiento
JYJuan Fernandez Yañez
Juan Fernandez Yañez
EBEmilio Bouza
Emilio Bouza

1 August 2014 in The Journal of Immunology
Verified
Journal Article
Closed access
GEGloria Esteso
Gloria Esteso
ELElisa Luzón
Elisa Luzón
ESElisabeth Sarmiento
Elisabeth Sarmiento
RGRuth Gómez-Caro
Ruth Gómez-Caro
ASAlexander Steinle
Alexander Steinle
Hugh Thomson ReyburnHugh Thomson Reyburn
Hugh Thomson Reyburn
Proteolytic shedding of ligands for the NK group 2D (NKG2D) receptor is a strategy used by tumors to modulate immune recognition by NK cells and cytotoxic T cells. A number of metalloproteases, especially those of the a disintegrin and metalloprotease (ADAM) family, can mediate NKG2D ligand cleavage and this process can be modulated by expression of the thiol isomerase ERp5. In this article, we describe that an increased shedding of the NKG2D ligand MICA is observed postinfection with several strains of human CMV due to an enhanced activity of ADAM17 (TNF-α converting enzyme) and matrix metalloprotease 14 caused by a reduction in the expression of the endogenous inhibitor of metalloproteases tissue inhibitors of metalloproteinase 3 (TIMP3). This decrease in TIMP3 expression correlates with increased expression of a cellular miRNA known to target TIMP3, and we also identify a human CMV–encoded microRNA able to modulate TIMP3 expression. These observations characterize a novel viral strategy to influence the shedding of cell-surface molecules involved in immune response modulation. They also provide an explanation for previous reports of increased levels of various ADAM17 substrates in the serum from patients with CMV disease. Consistent with this hypothesis, we detected soluble MICA in serum of transplant recipients with CMV disease. Finally, these data suggest that it might be worthwhile to prospectively study ADAM17 activity in a larger group of patients to assay whether this might be a useful biomarker to identify patients at risk for development of CMV disease.

1 January 2005 in International Immunopharmacology
Verified
Journal Article
Closed access
ESE. Sarmiento
E. Sarmiento
JFJ. Fernàndez-Yáñez
J. Fernàndez-Yáñez
PMP. Muñoz
P. Muñoz
JPJ. Palomo
J. Palomo
JRJ.J. Rodríguez-Molina
J.J. Rodríguez-Molina
JCJ. Carbone
J. Carbone

1 April 2011 in Expert Review of Anti-infective Therapy
Verified
Journal Article
Closed access
JCJavier Carbone
Javier Carbone
NPNadia del Pozo
Nadia del Pozo
AGAntonio Gallego
Antonio Gallego
ESElizabeth Sarmiento
Elizabeth Sarmiento
Immunosuppressive and biologic therapies are costly and can involve a considerable risk of infection. Noninvasive diagnostic tools for early prediction of infection before and after administration of these therapies are of major interest. Serial longitudinal immune monitoring would provide data on immunocompetence and complement clinical follow-up protocols. Biomarkers of immune response may be useful to identify patients at risk of developing infection and who could be candidates for immunosuppressant dose reduction. This article focuses on the potential use of biomarkers of immune response to predict development of infection after immunosuppressive and biologic therapies in selected settings of autoimmune disease (rituximab for treatment of rheumatoid arthritis) and solid organ transplantation.

30 March 2009 in The Journal of Rheumatology
Verified
Journal Article
Open access
PDF file
JCJavier Carbone
Javier Carbone
AGAntonio Gallego
Antonio Gallego
NLNallibe Lanio
Nallibe Lanio
JNJoaquin Navarro
Joaquin Navarro
MOMaria Orera
Maria Orera
ESElizabeth Sarmiento
Elizabeth Sarmiento
Objetive.: Few studies have assessed immunophenotypic abnormalities on lymphocyte subsets in patients with antiphospholipid syndrome (APS). We performed an extended immunological study to define alterations of distinct T, B, and natural killer (NK) cell subsets in obstetric patients with APS and their relationship with APS–associated complications.Methods.: Patients and controls: 36 women with APS [Sydney criteria, Group A1 without thrombosis (n = 26), Group A2 with thrombosis (n = 10)]; and 36 age matched women with recurrent abortion without antiphospholipid antibodies (disease controls; Group B), 36 healthy parous women (healthy controls; Group C), and 36 healthy nonparous women (healthy controls; Group D). Thrombotic events occurred after history of abortions in all A2 women. Three-color whole-blood flow cytometry was used to characterize the distinct immunophenotypes.Results.: A1 patients had significantly higher percentages of CD4+CD45RA–CCR7+ central memory cells (A1 vs D), higher percentages of activated CD4+CD25+ T cells (A1 vs D), and lower percentages and absolute counts of CD4+CD45RA–CCR7– effector memory cells (A1 vs D). GroupA2 patients had higher percentages and absolute numbers of CD19+CD27–IgD+ naive B cells (A2 vs A1 vs all controls), lower percentages and absolute numbers of CD3–CD56+CD16+ NK cells (A2 vs all controls), and higher percentages of activated CD4+DR+ (A2 vs all controls), CD8+DR+ (A2 vs A1 vs C vs D), CD4+CD38+DR+ (A2 vs D), and CD4+CD25+DR+ T cells (A2 vs all controls). Increased percentages of CD8+DR+ T cells [relative risk (RR) 2.43, 95% CI 1.09–5.44, p = 0.02] and of naive B cells (RR 3.05, 95% CI 1.30–7.11, p = 0.009) were associated with development of thrombosis.Conclusion.: In obstetric patients with APS we documented significant changes in T, B, and NK cell homeostasis. Increased levels of CD8+DR+ and CD19+CD27–IgD+ cells might identify obstetric patients with APS at risk of having thrombosis.

5 March 2009 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DSDiana Stauch
Diana Stauch
ADAnnelie Dernier
Annelie Dernier
EMElizabeth Sarmiento Marchese
Elizabeth Sarmiento Marchese
KKKristina Kunert
Kristina Kunert
HVHans-Dieter Volk
Hans-Dieter Volk
KKKatja Kotsch
Katja Kotsch
T cell depleting strategies are an integral part of immunosuppressive regimens widely used in the hematological and solid organ transplant setting. Although it is known to induce lymphocytopenia, little is known about the effects of the polyclonal rabbit antithymocyte globulin (rATG) or the monoclonal anti-CD52 antibody alemtuzumab on Natural Killer (NK) cells in detail. Here, we demonstrate that induction therapy with rATG following kidney/pancreas transplantation results in a rapid depletion of NK cells. Treatment of NK cells with rATG and alemtuzumab in vitro leads to impairment of cytotoxicity and induction of apoptosis even at a 10-fold lower concentration (0.1 µg/ml) compared with T and B cells. By generating Fc-parts of rATG and alemtuzumab we illustrate that their ligation to FcγRIII (CD16) is sufficient for the significant induction of degranulation, apoptosis and inflammatory cytokine release (FasL, TNFα and IFNγ) exclusively in CD3−CD56dim NK cells whereas application of rATG and alemtuzumab F(ab) fragments abolishes these effects. These findings are of general importance as our data suggest that NK cells are also mediators of the clinically relevant cytokine release syndrome and that their targeting by therapeutic antibodies should be considered as they are functionally relevant for the effective clearance of opportunistic viral infections and anti-tumor activity posttransplantation.